泌尿器科領域における 3-dimethyl carbamoylexy-1-methyl pyridinium bromide(Mestinon)の使用経験

Abstract

Mestinon was administered to 25 patients with neurogenic bladder and 3 with prostatic hypertrophy at daily dose of 180 mg (t.i.d.) for consecutive 2 to 51 days. Its effect was evaluated by cystometry, residual urine volume and subjective symptoms, 1) Of 21 neurogenic bladders due to spinal injury, it was effective in 8, fairly effective in 6, and non-effective in 7. 2) Of 4 neurogenic bladders not due to spinal injury, it was effective in 3 and noneffective in 1. 3) Of 3 benign prostatic hypertrophy, it was effective in 2 and not clear in 1. Above results showed that this drug is never inferior to the similar cholinesterase inhibitor and can be expected for clinical use.